ESOPHAGEAL CANCER
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A.
Incidence: <5/100,000 in U.S. ; <10/100,000 in Canada. gastroesophageal cancer of adenocarcinoma is on the rise as compare to squamous cell carcinoma of the esophagus. E. Esophageal cancer management modality options:
1.
Surgery:
Aim is to achieve R0 resection (complete resection of tumor). The 5 yr. survival after R0 resection is 15-20%. The median survival is about 18 months.
Radiation Therapy:
Randomized prospective trial ( Radiation Therapy Oncology Group-RTOG 8501 ) showed that radiation alone of 64Gy at 2Gy/fx, 3yr. survival rate is zero. Radiation therapy alone reserved for palliation or for medically unable to receive chemotherapy. Pre-op. or post-op. radiation therapy has been shown to have no survival benefit. Post-op radiation therapy can offer local control benefit in high risk patients. ( Fok et al,Surg 1993 ,Teniere et al., Surg Gyn 1991 .
3.
Chemoradiation:
Randomized prospective trial (RTOG 8501) also showed that combined chemo (5FU/Cisp) + radiation therapy (50Gy) has survival benefit over radiation therapy (64Gy) alone. The 5 yr. overall survival (OS ) of combined modality is superior (27%) than radiation therapy alone (0%) , median survival 14 mos.(month) of combined versus (VS) 9 mos. of radiation alone. Local failure rate of combined chemoradiation is also superior ( 47% ) over radiation alone( 65% JCO 2001; Walsh et al, NEJM 1997; Bosset et al, NEJM 1997; Burmeister et al, Proc.ASCO 2002 ; Malthaner et al, BMC Cancer 2004) .
4.
Brachytherapy:
It is used mainly for palliation when given alone. It has local control of 25-35%, median OS of 5 mos.
RTOG 9207 combined modality(5FU/Cisp/50Gy) followed by intra-luminal brachytherapy boost, local failure rate of 27%; acute toxicity Grade 3-5 58%, 26%, 8% ,respectively; fistula rate of 18%/yr. ; therefore , at the present time brachytherapy is not recommended by the American Brachytherapy Society as a boost when using with high dose rate concurrent with chemotherapy.
5.
Chemotherapy: It is used mainly for palliation when given alone. Pre-op chemotherapy may provide small benefit in survival over surgery alone. Confirmative result is pending (Int.0113 study, Thirion et al , Proc ASCO , 2007 ) .
Chemotherapy agents for esophageal cancer include : Cisplatinum, most active, >20% response rate. Others include 5FU, Mitomyc. Bleomyc, Doxorub, Vind, Paclit, Vinorel. 5FU + Cisp combination has response rate of 20-50%.
Endoscopic palliation:
Laser Ballon dilation Photodynamic Intracavitary irradiation and plastic or expandible metal prothesis, all of above is for symptom control only.
MANAGEMENT SUMMARY :
Trimodality management of resectable esophageal cancer is evolving, many cancer centers favour the neoadjuvant management ( chemoradiation followed by surgery) although final confirmative result is pending.
There is no clinical trial comparing the benefit of neoadjuvant VS adjuvant resectable esophageal cancer.
At London Regional Cancer Program (LRCP) :
Esophageal cancer that is operable, resectable T 1 -T 3 The recommended management is: Esophagectomy After complete resection: o If N 0 , the management is observation only. o If N 1 , (or resection margins involvement) the recommended management is post -op chemoradiation.
Esophageal cancer that is operable, resectable T 1 -T 3 It is not unreasonable to offer concurrent chemotherapy (5FU/Cisp) + radiation therapy (50Gy) as an alternative treatment option besides surgery ( RTOG 8501). Survival can approach that of surgery alone in some circumstances.
Esophageal cancer that is inoperable T 4 , or surgery refusal The recommended management is concurrent chemoradiation .
Inoperable disease and patient is unable to tolerate chemotherapy , the management can be best supportive care.
Best supportive care includes the following:
o Obstruction-stent, laser, photodynamic therapy. o Radiation therapy (xrt )(external beam, brachytherapy). o Nutrition -external feeding( J-tube). o Pain control -xrt/medications. o Bleeding -xrt/surgery/endoscopic therapy.
